Overview
| Trade Names: | Anabet; Corgard; Solgol |
|---|---|
| Brand Mixtures: | Corzide Tab W Nadolol 40mg (Bendroflumethiazide + Nadolol); Corzide Tab W Nadolol 80mg (Bendroflumethiazide + Nadolol) |
| PharmGKB Accession Id: | PA450573 |
Description
A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. PubChem (source: Drug Bank)
Indication
Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. (source: Drug Bank)
ATC Therapeutic Category
- C07AA:Beta blocking agents, non-selective
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. (source: Drug Bank)
Pharmacology
Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. (source: Drug Bank)
Food Interactions
Avoid alcohol.
Avoid natural licorice.
Magnesium, potassium and zinc needs increased.
Take without regard to meals.
(source:
Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Not metabolized by the liver and excreted unchanged primarily by the kidneys. (source: Drug Bank)
Protein Binding
30% (source: Drug Bank)
Absorption
Absorption of nadolol after oral dosing is variable, averaging about 30 percent. (source: Drug Bank)
Toxicity
Oral, mouse: LD<sub>50</sub> = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing. (source: Drug Bank)
Isomeric SMILES Code:
CC(C)(C)NCC(COc1cccc2c1C[C@@H]([C@@H](C2)O)O)O (source: Drug Bank)
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| ADRB1 |
|
(source: Drug Bank) |
| ADRB2 |
|
(source: Drug Bank) |
PharmGKB Curated Pathways
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| Methyldopa |
|
Possible hypertensive crisis (source: Drug Bank) |
| acetohexamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| aminophylline |
|
Antagonism of action and increased effect of theophylline (source: Drug Bank) |
| chlorpropamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| clonidine |
|
Increased hypertension when clonidine stopped (source: Drug Bank) |
| dihydroergotamine |
|
Ischemia with risk of gangrene (source: Drug Bank) |
| dihydroergotoxine |
|
Ischemia with risk of gangrene (source: Drug Bank) |
| disopyramide |
|
The beta-blocker increases toxicity of disopyramide (source: Drug Bank) |
| dyphylline |
|
Antagonism of action and increased effect of theophylline (source: Drug Bank) |
| epinephrine |
|
Hypertension, then bradycardia (source: Drug Bank) |
| ergonovine |
|
Ischemia with risk of gangrene (source: Drug Bank) |
| ergotamine |
|
Ischemia with risk of gangrene (source: Drug Bank) |
| fenoterol |
|
Antagonism (source: Drug Bank) |
| formoterol |
|
Antagonism (source: Drug Bank) |
| glibenclamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| gliclazide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| glipizide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| glisoxepide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| glycodiazine |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| ibuprofen |
|
Risk of inhibition of renal prostaglandins (source: Drug Bank) |
| indomethacin |
|
Risk of inhibition of renal prostaglandins (source: Drug Bank) |
| isoproterenol |
|
Antagonism (source: Drug Bank) |
| l-methyldopa |
|
Possible hypertensive crisis (source: Drug Bank) |
| lidocaine |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| methysergide |
|
Ischemia with risk of gangrene (source: Drug Bank) |
| orciprenaline |
|
Antagonism (source: Drug Bank) |
| oxtriphylline |
|
Antagonism of action and increased effect of theophylline (source: Drug Bank) |
| pirbuterol |
|
Antagonism (source: Drug Bank) |
| piroxicam |
|
Risk of inhibition of renal prostaglandins (source: Drug Bank) |
| prazosin |
|
Risk of hypotension at the beginning of therapy (source: Drug Bank) |
| procaterol |
|
Antagonism (source: Drug Bank) |
| repaglinide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| salbutamol |
|
Antagonism (source: Drug Bank) |
| salmeterol |
|
Antagonism (source: Drug Bank) |
| terbutaline |
|
Antagonism (source: Drug Bank) |
| theophylline |
|
Antagonism of action and increased effect of theophylline (source: Drug Bank) |
| tolazamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| tolbutamide |
|
The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank) |
| verapamil |
|
Increased effect of both drugs (source: Drug Bank) |
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.
